SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) — Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the first patient has been dosed in the Phase 1/2 clinical trial (NCT07300241) evaluating NEO-811, a novel investigational molecular glue degrader, in patients with locally advanced or metastatic non-resectable clear cell […]

Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma Initiation of trial marks first-in-human milestone for Neomorph's novel molecular glue degrader platform GlobeNewswire February 03, 2026 SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) — Neomorph, Inc., a biotechnology company

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Varonis Systems, Inc. of Class Action Lawsuit and Upcoming Deadlines – VRNS GlobeNewswire February 03, 2026 NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Varonis Systems, Inc. (“Varonis” or the

Zaya Younan Is Planning and Designing the World's Largest and Most Efficient Solar Power Plant GlobeNewswire February 03, 2026 Los Angeles, CA, Feb. 03, 2026 (GLOBE NEWSWIRE) — Zaya Younan, Founder and Chairman of Younan Company, today announced plans to architect and develop what is intended to become the world's largest and most efficient renewable

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Navan, Inc. – NAVN GlobeNewswire February 03, 2026 NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Navan, Inc. (“Navan” or the “Company”) (NASDAQ: NAVN). Such investors are advised to contact Danielle Peyton at

Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy and a significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM) Interim readout expected in 2H 2026 MIAMI, Feb. 03, 2026 (GLOBE NEWSWIRE) — RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell

RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy GlobeNewswire February 03, 2026 Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy and a significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM) Interim readout expected

NEW YORK CITY, NY / ACCESS Newswire / February 3, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Picard Medical, Inc. (NYSE:PMI) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the

Brokerage Model Helps Agents Increase Earning Potential and Scale Their Book by Absorbing Operations, Compliance, and Carrier Management Mavrix Insurance Services today launched a centralized insurance brokerage model designed to eliminate the operational and servicing demands that prevent independent agents from scaling. The model removes the need for agents to manage carrier appointments, account servicing,

CathWorks, a global leader in digital health innovations, announced that the Society for Cardiovascular Angiography & Interventions (SCAI) published an expert opinion discussing the expanding role of angiography-derived physiology (ADP), a wire-free method for coronary physiologic assessment. By applying different principles, in some cases in conjunction with artificial intelligence (AI), ADP provides physiologic insights from